BriaCell Therapeutics Corp (NASDAQ:BCTX)’s traded shares stood at 9.68 million during the latest session, with the company’s beta value hitting 1.33. At the last check today, the stock’s price was $3.29, to imply a decrease of -3.52% or -$0.12 in intraday trading. The BCTX share’s 52-week high remains $29.40, putting it -793.62% down since that peak but still an impressive 14.59% since price per share fell to its 52-week low of $2.81.
BriaCell Therapeutics Corp (NASDAQ:BCTX) trade information
After registering a -3.52% downside in the latest session, BriaCell Therapeutics Corp (BCTX) has traded red over the past five days. The 5-day price performance for the stock is 11.90%, and -45.44% over 30 days. With these gigs, the year-to-date price performance is -61.18%.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 47.85% for the past 5-year period. While 2025 is set for a -16.33% return in earnings, projections for the next 5 years are at 31.60% annually.
BCTX Dividends
BriaCell Therapeutics Corp has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Going by data provided on Mar 31, 2025 , Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund holds roughly 481.0 shares. This is just over 0.01% of the total shares, with a market valuation of $1553.0
